Display options
Cite
Murrieta-Álvarez I, Cantero-Fortiz Y, León-Peña AA, et al. The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge. Front Neurol. 2021;12:647425doi: 10.3389/fneur.2021.647425.
Murrieta-Álvarez, I., Cantero-Fortiz, Y., León-Peña, A. A., Olivares-Gazca, J. C., Priesca-Marín, J. M., Ruiz-Delgado, G. J., Gómez-De-León, A., Gonzalez-Lopez, E. E., Jaime-Pérez, J. C., Gómez-Almaguer, D., & Ruiz-Argüelles, G. J. (2021). The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge. Frontiers in neurology, 12647425. https://doi.org/10.3389/fneur.2021.647425
Murrieta-Álvarez, Iván, et al. "The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge." Frontiers in neurology vol. 12 (2021): 647425. doi: https://doi.org/10.3389/fneur.2021.647425
Murrieta-Álvarez I, Cantero-Fortiz Y, León-Peña AA, Olivares-Gazca JC, Priesca-Marín JM, Ruiz-Delgado GJ, Gómez-De-León A, Gonzalez-Lopez EE, Jaime-Pérez JC, Gómez-Almaguer D, Ruiz-Argüelles GJ. The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge. Front Neurol. 2021 Feb 22;12:647425. doi: 10.3389/fneur.2021.647425. eCollection 2021. PMID: 33692748; PMCID: PMC7937693.
Copy Download .nbib Format: NLM
Share it on

Front Neurol. 2021 Feb 22;12:647425. doi: 10.3389/fneur.2021.647425. eCollection 2021.

The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-México Program: A Myriad of Experiences and Knowledge.

Frontiers in neurology

Iván Murrieta-Álvarez, Yahveth Cantero-Fortiz, Andrés A León-Peña, Juan C Olivares-Gazca, José Manuel Priesca-Marín, Guillermo J Ruiz-Delgado, Andrés Gómez-De-León, Elías Eugenio Gonzalez-Lopez, José Carlos Jaime-Pérez, David Gómez-Almaguer, Guillermo J Ruiz-Argüelles

Affiliations

  1. Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico.
  2. Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico.
  3. Escuela de Medicina, Universidad de las Américas Puebla, Puebla, Mexico.
  4. Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
  5. Laboratorios Clínicos de Puebla, Puebla, Mexico.
  6. Clínica Gómez Almaguer, Monterrey, Mexico.
  7. Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico.

PMID: 33692748 PMCID: PMC7937693 DOI: 10.3389/fneur.2021.647425

Abstract

After gaining experience conducting both auto and allografts in persons with hematological diseases in the HSCT programs in Puebla and Monterrey, México, this study outlines subsequent program autografting patients with autoimmune conditions. The first transplant in multiple sclerosis was conducted in Puebla on July 5, 2006. From 2015 we increased activity autografting persons with autoimmune conditions in the two campuses of the HSCT-México program: Puebla and Monterrey. By December 6, 2020, patient number 1,000 in the program was autografted. In our experience, a significant reduction in the expanded disability status scale score was achieved in all of the three phenotypes of the disease (from a median of 5.1 to 4.5 points), whereas the response rate (defined as a decrease of at least 0.5 of EDSS score regardless of baseline EDSS, or unchanged EDSS) was 83, 78, and 73% after 12 months in the relapsing-remitting, primary-progressive and secondary-progressive forms of multiple sclerosis, respectively. In addition to analyzing the viability, safety, and efficacy of our method, this study contributes new knowledge to the field of both stem cell transplantation and multiple sclerosis.

Copyright © 2021 Murrieta-Álvarez, Cantero-Fortiz, León-Peña, Olivares-Gazca, Priesca-Marín, Ruiz-Delgado, Gómez-De-León, Gonzalez-Lopez, Jaime-Pérez, Gómez-Almaguer and Ruiz-Argüelles.

Keywords: HSCT; PBSCs; autoimmune diseases; cyclophosphamide; multiple sclerosis; non-myeloablative; outpatient care

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. J Glob Oncol. 2018 Sep;4:1 - PubMed
  2. Clin Exp Immunol. 2019 Dec;198(3):351-358 - PubMed
  3. Clin Transplant. 2019 Jun;33(6):e13567 - PubMed
  4. Lab Med. 2019 Jan 1;50(1):42-46 - PubMed
  5. Nat Rev Neurol. 2017 Jul;13(7):391-405 - PubMed
  6. Neurol Ther. 2020 Dec;9(2):197-203 - PubMed
  7. Acta Haematol. 2017;137(4):214-219 - PubMed
  8. Biol Blood Marrow Transplant. 2017 Nov;23(11):1815-1816 - PubMed
  9. Neurology. 2017 Feb 28;88(9):842-852 - PubMed
  10. J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1116-21 - PubMed
  11. Rev Invest Clin. 2016 Jul-Aug;68(4):181-3 - PubMed
  12. Hematology. 2020 Dec;25(1):320 - PubMed
  13. Arch Intern Med. 1981 May;141(6):758-63 - PubMed
  14. JAMA Neurol. 2017 Apr 1;74(4):459-469 - PubMed
  15. Lancet Haematol. 2020 Jul;7(7):e509-e510 - PubMed
  16. Mult Scler Relat Disord. 2018 Oct;25:316-321 - PubMed
  17. JAMA. 2019 Jan 15;321(2):165-174 - PubMed
  18. Biol Blood Marrow Transplant. 2019 May;25(5):845-854 - PubMed
  19. Cytotherapy. 2020 Mar;22(3):144-148 - PubMed

Publication Types